Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2023;34(4):570-2
Article Links
A Challenging Inflammatory Myopathy Case-Report: Dermatomyositis-Like Rash in an Anti-HMGCR Positive Patient with an Uncertain Muscle Histology
Hugo Parente1, Maria Pontes Ferreira1, Catarina Soares1, Emanuel Costa2, Francisca Guimarães1, Soraia Azevedo1, Daniela Santos-Faria1, José Tavares-Costa1, Daniela Peixoto1, Carmo Afonso1, Filipa Teixeira1
Authors Information

1Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal

2Rheumatology Department, Hospital de Braga, Braga, Portugal

H Parente

Keywords: Anti-HMGCR, heliotrope, necrotising myopathy, inflammatory myopathy
References
  1. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 2016;29(5):662-73.
  2. Allenbach Y, Benveniste O. Peculiar clinicopathological features of immune-mediated necrotizing myopathies. Curr Opin Rheumatol 2018;30(6): 655-63.
  3. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63(3):713-21.
  4. Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014;93(3):150-7.
  5. Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin J, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012;64(2):269-72.
  6. Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C, et al. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev 2016;15(10):983-93.
  7. Hudson M, Luck Y, Stephenson M, Choi MY, Wang M, Baron M, et al. Anti-HMGCR antibodies in systemic sclerosis. Medicine (Baltimore) 2016;95(44): e5280.
  8. Troyanov Y, Landon-Cardinal O, Fritzler MJ, Ferreira J, Targoff IN, Rich E, et al. Atorvastatin-induced necrotizing autoimmune myositis: an emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype. Medicine (Baltimore)2017;96(3):e5694.
  9. Lavian M, Mozaffar T, Goyal N. Clinical dermatomyositis associated with anti-HMG-CoA reductase antibody positive immune mediated necrotizing myopathy: a case report (P2.125). Neurology 2017;88(16 Supplement):P2125.
  10. Merlant M, Fite C, Kottler D, Maisonobe L, Dossier A, Deschamps L, et al. [Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies]. Ann Dermatol Venereol 2019;146(8-9):550-6.
  11. Parikh P, Tavee J, Soltanzadeh P, Mammen AL, McKeever P, Li Y. Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibody-positive necrotizing autoimmune myopathy with dermatomyositis-like eruption. Muscle Nerve 2018;57(6):E135-E136.
  12. Lim D, Landon-Cardinal O, Ellezam B, Belisle A, Genois A, Sirois J, et al. Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report. SAGE Open Med Case Rep 2020 Dec 29;8:2050313X20984120. doi: 10.1177/2050313X20984120. PMID: 33447390; PMCID: PMC7780312.
  13. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 2016;29:662-73.
  14. Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018;28(1):87-99.
  15. Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med 2016;374:664-9.
  16. Basharat P, Lahouti AH, Paik JJ, Albayda J, Pinal-Fernandez I, Bichile T, et al. Statin-Induced Anti-HMGCR-Associated Myopathy. J Am Coll Cardiol 2016;68:234-5.
  17. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology 2015;54(3):383-91.
  18. Wang DX, Shu XM, Tian XL, Chen F, Zu N, Ma L, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: A systematic literature review. Clin Rheumatol 2012;31(5):801-6.
  19. Kampylafka EI, Kosmidis ML, Panagiotakos DB, Dalakas M, Moutsopoulos HM, Tzioufas AG. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: A 4-year follow-up study. Clin Exp Rheumatol 2012;30(3):397-401.
  20. Uruha A, Allenbach Y, Charuel JL, Musset L, Aussy A, Boyer O, et al. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol 2019;45(5):513-22.